RxDoctor Payments Data

Diana Plata, MD

Obesity Medicine · Arlington Heights, ILNPI 1619329380

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (56.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Lilly USA, LLC at 57.2% of the total. 2025 is the largest year on record at $17,892, more than ten times the $231 reported in 2023.

$18,635in general payments, 2019–2025

Across 52 payments — averaging $358.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$11K
  • Eli Lilly$4K
  • Novo Nordisk$3K
  • Jazz Pharmaceuticals Inc.$169
  • Currax Pharmaceuticals LLC$102

What the payments were for

  • Consulting fees$6,60535%
  • Speaking & faculty fees$10,50056%
  • Travel & lodging$2751%
  • Food & beverage$1,2237%
  • Education$320%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few obesity medicine providers in Illinoisto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$67,177
Medicare patients
112
Services billed
723

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$86,078
MounjaroTirzepatide40$49,833
WegovySemaglutide27$38,795
Naltrexone Hcl30$922
Topiramate91$712
Metformin Hcl ErMetformin Hcl55$457
Trazodone Hcl11$13

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$3,400$124,87392 claims
Lilly USA, LLCMounjaro$10,665$49,83340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few obesity medicine providers in Illinoison file to place this against a meaningful peer group, so we don't.

Other obesity medicine in Arlington Heights

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →